The study develops a novel photothermal agent, nickel sulfide (Ni3S4) nanoprisms (NPs), combined with the phase change material (PCM) having high biocompatibility and chemotherapy drug, doxorubicin (DOX), as the new anti-cancer agent (Ni3S4-DOX-PCM). With a full-spectrum-absorption (400 -1100 nm) in the NIR region, Ni3S4 NPs can be triggered by the NIR II laser (1000 -1500 nm) with deeper tissue penetration. The feature will improve the photothermal effect of deep-seated tumor and expand the application range of photothermal therapy. In addition, the use of PCM to encapsulate the Ni3S4 NPs and DOX stabilizes the structure of Ni3S4 NPs to exhibit the good photothermal effect, greatly enhance the biocompatibility of Ni3S4, and reduce the cytotoxicity of DOX on normal cell. When the drug accumulates in tumor and triggered by the laser, the photothermal effect not only as the thermotherapy but also loosen the PCM structure to release the DOX to kill the cancer cells, achieving the synergistic photo-chemotherapy.